Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Last Close
Dec 04 04:00PM ET
1.94
Dollar change
0.00
Percentage change
0.00
%
Index- P/E- EPS (ttm)-0.74 Insider Own4.59% Shs Outstand208.62M Perf Week-9.35%
Market Cap404.77M Forward P/E- EPS next Y-0.16 Insider Trans0.00% Shs Float199.07M Perf Month11.49%
Income-136.13M PEG- EPS next Q-0.10 Inst Own27.00% Short Float6.73% Perf Quarter158.22%
Sales52.29M P/S7.74 EPS this Y66.55% Inst Trans-35.54% Short Ratio1.81 Perf Half Y231.40%
Book/sh0.19 P/B10.34 EPS next Y68.18% ROA-82.26% Short Interest13.39M Perf Year300.17%
Cash/sh0.19 P/C10.33 EPS next 5Y- ROE-156.42% 52W Range0.30 - 3.18 Perf YTD257.08%
Dividend Est.- P/FCF- EPS past 5Y-15.96% ROI-203.60% 52W High-38.97% Beta1.18
Dividend TTM- Quick Ratio1.35 Sales past 5Y17.84% Gross Margin80.48% 52W Low538.16% ATR (14)0.28
Dividend Ex-Date- Current Ratio1.35 EPS Y/Y TTM48.16% Oper. Margin-256.68% RSI (14)48.28 Volatility12.39% 15.86%
Employees405 Debt/Eq0.71 Sales Y/Y TTM-74.04% Profit Margin-260.33% Recom2.12 Target Price6.20
Option/ShortYes / Yes LT Debt/Eq0.71 EPS Q/Q107.45% Payout- Rel Volume0.00 Prev Close1.94
Sales Surprise136.17% EPS Surprise361.44% Sales Q/Q425.77% EarningsNov 12 AMC Avg Volume7.40M Price1.94
SMA20-13.66% SMA5020.41% SMA200112.33% Trades Volume0 Change0.00%
Date Action Analyst Rating Change Price Target Change
Nov-03-23Downgrade RBC Capital Mkts Outperform → Sector Perform $6 → $2
Apr-28-23Downgrade BofA Securities Neutral → Underperform $5 → $1.50
Feb-27-23Upgrade Wedbush Neutral → Outperform $16
Jan-06-23Downgrade BofA Securities Buy → Neutral $8 → $5
Jun-13-22Resumed Wedbush Neutral $5
May-04-21Initiated RBC Capital Mkts Outperform $22
Jan-07-21Resumed Guggenheim Neutral $16
Jan-06-21Initiated Stifel Hold $16
Dec-16-20Resumed H.C. Wainwright Buy $25
Sep-08-20Initiated BofA Securities Buy $20
Nov-19-24 04:15PM
Nov-13-24 09:49AM
02:16AM
Nov-12-24 05:15PM
04:09PM
04:01PM Loading…
04:01PM
Nov-04-24 04:15PM
Oct-23-24 07:45AM
Oct-22-24 08:05AM
Aug-07-24 01:24PM
04:32AM
Aug-06-24 05:35PM
04:37PM
04:01PM
08:11AM
08:05AM Loading…
08:05AM
Jul-30-24 04:15PM
Jul-24-24 06:55AM
May-12-24 08:28AM
May-10-24 03:58PM
May-09-24 08:58PM
05:25PM
04:23PM
04:01PM
10:46AM
08:05AM
May-02-24 04:15PM
Apr-22-24 04:35PM
Mar-22-24 08:05AM
Mar-14-24 07:23AM
08:21AM Loading…
Mar-13-24 08:21AM
08:05AM
08:01AM
Mar-12-24 06:30PM
Feb-12-24 08:05AM
Feb-05-24 06:01PM
Nov-03-23 05:03PM
Nov-02-23 08:15AM
Nov-01-23 07:05PM
04:13PM
04:01PM
Oct-26-23 10:02AM
Oct-25-23 04:15PM
Oct-24-23 02:01AM
Sep-20-23 04:15PM
Aug-25-23 01:38PM
Aug-08-23 05:30PM
04:26PM
04:01PM
Aug-01-23 04:15PM
Jul-20-23 08:05AM
Jul-19-23 07:08AM
Jul-17-23 08:05AM
Jun-29-23 08:05AM
Jun-28-23 09:20AM
Jun-14-23 08:16AM
May-22-23 08:05AM
May-18-23 07:04AM
May-16-23 08:00AM
May-02-23 04:30PM
06:03AM
Apr-26-23 05:28PM
Apr-25-23 02:39PM
Apr-21-23 04:58AM
Apr-19-23 04:15PM
Apr-17-23 07:38AM
Apr-16-23 06:30AM
Mar-23-23 06:09AM
Mar-21-23 09:35AM
Mar-20-23 12:25PM
Mar-10-23 09:35AM
Feb-25-23 08:26AM
Feb-23-23 05:36PM
11:57AM
Feb-22-23 05:25PM
04:01PM
03:01PM
09:35AM
Feb-21-23 09:01AM
Feb-16-23 10:01AM
Feb-13-23 09:55AM
Feb-10-23 11:01AM
Jan-30-23 07:10PM
Dec-06-22 06:02AM
Nov-09-22 05:31AM
Nov-03-22 05:55PM
04:01PM
Oct-27-22 04:15PM
Oct-14-22 09:49AM
Oct-12-22 08:55AM
03:01AM
Sep-23-22 12:02PM
Sep-18-22 09:11AM
Aug-30-22 08:50AM
06:00AM
Aug-29-22 09:55AM
Aug-12-22 09:55AM
Aug-04-22 05:45PM
04:01PM
Jul-28-22 04:15PM
Sangamo Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the research and development of zinc finger proteins. It focuses on three therapeutic areas: inherited metabolic diseases, central nervous system, and diseases and immunology, which consist of inflammatory and autoimmune diseases. It also offers complementary technology platforms such as gene therapy, ex vivo cell therapy, in vivo genome editing, and in vivo genome regulation. The company was founded by Edward O. Lanphier II in 1995 and is headquartered in Richmond, CA.